Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer. Cleave has ongoing collaborations with the National Cancer Institute (NCI) and leading academic institutions. The company is leveraging this combined expertise to advance VCP/p97 inhibitors for cancer and neurodegenerative disease.
VCP is a critical enzyme in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases and is a key regulator of various aspects of protein homeostasis and cellular stress that are critical for cancer cell growth and survival. In neurodegenerative diseases, VCP/p97 has been shown to be important for the health and function of mitochondria, and Cleave’s research has demonstrated the potential for therapeutic benefit for patients with limited treatment options with those devastating diseases.
Cleave’s oncology drug discovery pipeline exploits molecular features that are dependent on VCP/p97 and are key to the growth and survival of cancers cells. Cleave’s lead drug development candidate, CB-5339, is a potent, oral, selective, second-generation inhibitor of VCP/p97, which addresses the limitations of earlier compounds, including exposure and selectivity to the target. The company is launching a Phase 1 clinical study in acute myeloid leukemia (AML), for which there is compelling preclinical data and a significant unmet medical need. The National Cancer Institute has a decades long interest in VCP/p97 as a target and is planning to sponsor a Phase I trial with CB-5339 in solid tumors.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 135 Main St,
- Phone
- (415) 562-8117
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cleavetherapeutics.com
- Keywords
- biotechnology, oncology, drug discovery, drug development, cancer, neurodegeneration, protein homeostasis.
- HQ
- San Francisco, California
Cleave Therapeutics, Inc. Questions
Cleave Therapeutics, Inc.'s helpline number is (415) 562-8117
Cleave Therapeutics, Inc.'s website is cleavetherapeutics.com
Cleave Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/cleavetherapeutics
Cleave Therapeutics, Inc. has
3 employees.
View email and phone details for 3
employees at Cleave Therapeutics, Inc..
Cleave Therapeutics, Inc.'s industry is
Biotechnology Research
Cleave Therapeutics, Inc.'s top competitors are
Essa Pharma,
Amgen,
Onyx Pharmaceuticals, Inc., An Amgen Subsidiary,
Capacity Bio,
Tenaya Therapeutics,
Crinetics Pharmaceuticals,
Howard Hughes Medical Institute (Hhmi),
Terns Pharmaceuticals,
Global Blood Therapeutics,
Eikon Therapeutics.
Cleave Therapeutics, Inc.'s support email address is info@cleavetherapeutics.com
Cleave Therapeutics, Inc.'s categories are Biotechnology Research
Cleave Therapeutics, Inc.'s founding year is 2011
